Yulin Li

Yulin Li, MD, PhD

Assistant Professor of Immunotherapy in Oncology, Academic Institute
Assistant Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Li Lab


Biography

Dr. Li finished his medical school at Beijing Medical University and his graduate school at Penn State. He had his postdoctoral training at Stanford University before joining the Research Institute in late 2017.

Description of Research

Dr. Li's research interest includes 1) non-genetic mechanisms of therapeutic resistance, and 2) rational combination therapy.  Dr. Li's lab utilizes both experimental and computational approaches to study cancer biology and therapeutics.

Areas Of Expertise

Proteomics in oncology Combination therapy Differentiation Chemoresistance CRISPR
Publications

Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R, Sullivan, DK, Azizian, NG, Liu, Y & Li, Y 2021, , BMC Cancer, vol. 21, no. 1, 237. https://doi.org/10.1186/s12885-021-07967-6

Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo
Li, Y 2020, , Journal of Proteome Research. <https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00666>

Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo
Azizian, NG, Sullivan, DK, Nie, L, Pardo, S, Molleur, D, Chen, J, Weintraub, ST & Li, Y 2020, , Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.0c00666

Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Li, Y 2020, , BMC Cancer.

XPO1-dependent nuclear export as a target for cancer therapy
Azizian, NG, Azizian, NG, Li, Y & Li, Y 2020, , Journal of Hematology and Oncology, vol. 13, no. 1, 61. https://doi.org/10.1186/s13045-020-00903-4

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
Liu, Y, Azizian, NG, Dou, Y, Pham, LV & Li, Y 2019, , Journal of Hematology and Oncology, vol. 12, no. 1. https://doi.org/10.1186/s13045-019-0803-9

Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index
Li, Y, Thomas, D, Deutzmann, A, Majeti, R, Felsher, DW & Dill, DL 2019, , Scientific Reports, vol. 9, no. 1, pp. 16775. https://doi.org/10.1038/s41598-019-53290-3

Rational targeted therapeutics for double-hit lymphoma
Azizian, NG, Liu, Y, Pham, LV & Li, Y 2019, , International Journal of Hematologic Oncology, vol. 8, no. 3, pp. IJH19. https://doi.org/10.2217/ijh-2019-0009

Rational Targeted Therapeutics for Double-Hit Lymphoma
Li, Y 2019, International Journal of Hematologic Oncology.

BIM-mediated apoptosis and oncogene addiction
Li, Y, Deutzmann, A & Felsher, DW 2016, , Aging, vol. 8, no. 9, pp. 1834-1835. https://doi.org/10.18632/aging.101072

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia
Li, Y, Deutzmann, A, Choi, PS, Fan, AC & Felsher, DW 2016, , Oncotarget, vol. 7, no. 19, pp. 26926-26934. https://doi.org/10.18632/oncotarget.8731

MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, SC, Tong, L, Li, Y, Do, R, Walz, S, Fitzgerald, KN, Gouw, AM, Baylot, V, Gütgemann, I, Eilers, M & Felsher, DW 2016, , Science, vol. 352, no. 6282, pp. 227-231. https://doi.org/10.1126/science.aac9935

Erratum: MYC regulates the antitumor immune response through CD47 and PD-L1 (Science (2016) 352:6282)
Casey, SC, Tong, L, Li, Y, Do, R, Walz, S, Fitzgerald, KN, Gouw, AM, Baylot, V, Gütgemann, I, Eilers, M & Felsher, DW 2016, , Science, vol. 352, no. 6282. https://doi.org/10.1126/science.aaf7984

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
Shroff, EH, Eberlin, LS, Dang, VM, Gouw, AM, Gabay, M, Adam, SJ, Bellovin, DI, Trand, PT, Philbrick, WM, Garcia-Ocana, A, Casey, SC, Li, Y, Dang, CV, Zare, RN & Felsher, DW 2015, , Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 21, pp. 6539-6544. https://doi.org/10.1073/pnas.1507228112

miR-17–92 explains MYC oncogene addiction
Li, Y, Casey, SC, Choi, PS & Felsher, DW 2014, , Molecular and Cellular Oncology, vol. 1, no. 4, e970092. https://doi.org/10.4161/23723548.2014.970092

Activation of cre recombinase alone can induce complete tumor regression
Li, Y, Choi, PS, Casey, SC & Felsher, DW 2014, , PLoS ONE, vol. 9, no. 9, e0107589. https://doi.org/10.1371/journal.pone.0107589

Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance
Choi, PS, Li, Y & Felsher, DW 2014, , Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 32, pp. E3316-E3324. https://doi.org/10.1073/pnas.1406123111

MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a Neoplastic state
Li, Y, Choi, PS, Casey, SC, Dill, DL & Felsher, DW 2014, , Cancer Cell, vol. 26, no. 2, pp. 262-272. https://doi.org/10.1016/j.ccr.2014.06.014

Oncogene withdrawal engages the immune system to induce sustained cancer regression
Casey, SC, Li, Y, Fan, AC & Felsher, DW 2014, , Journal for immunotherapy of cancer, vol. 2, no. 1, 24. https://doi.org/10.1186/2051-1426-2-24

Inactivation of MYC reverses tumorigenesis
Li, Y, Casey, SC & Felsher, DW 2014, , Journal of Internal Medicine, vol. 276, no. 1, pp. 52-60. https://doi.org/10.1111/joim.12237